MIVT.OB~~Sector: Healthcare~~Industry: Medical Equipment & Supplies

[setravis]

Wow setravis, awesome picks!

Thanks Irod. I hope the traders here @ 3SOF bought in to some
of these picks and made a nice return.Team work on this site will make us all
a nice return.

[setravis]

This has been a nice one.
Had no trouble breaking the $1.00...A pure display of power!
Support @ 0.84...1.02...1.20
MACD and Stochastic are very bullish
Big volume Friday....Nice big white candlestick
You have to look back with a 5 year chart to see the last time these price levels
were hit by this stock and that was early 2002, around the $1.75 area.
The $2.50 area in mid-2001...and the $3.00 area around the middle of 2001.
Those levels could be used as possible targets.
Pull up a 5 year chart and check it out.......This baby is nice...
The talk is this one will keep going because of the NANO TECH.

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
47.66%above 13-day EMA
91.73%above 50-day EMA

[422fwhp]

Wow, very nice job.  This thing has legs!

What do you expect from here?  I wish to enter but may have to wait for a pullback...sometime...


Thanks...Jody

[422fwhp]

Here's Friday's news...

MIVT Receives Prestigious Frost & Sullivan 2005 Award for Technology Innovation in Field of Medical Coatings

VANCOUVER, British Columbia, Aug. 26 /PRNewswire-FirstCall/ -- MIV Therapeutics, Inc. (OTC Bulletin Board: MIVT - News), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, has been recognized by Frost & Sullivan with the 2005 Technology Innovation Award, in recognition of the Company's achievements and pioneering work to develop proprietary biocompatible coatings technology to make better, safer vascular stents, medical devices and drug delivery systems.

Frost & Sullivan, a widely respected global independent research and growth consulting firm presents the annual Technology Innovation Award to recognize the quality and depth of a company's research and development program, as well as the vision that enabled it to undertake such an endeavor. Frost & Sullivan's Technology Innovation Award is bestowed upon a company or individual that has carried out new research that has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The selection process includes primary participant interviews and extensive primary and secondary research.

"MIV Therapeutics has utilized an entirely new approach for medical coatings vis-a-vis the classic polymer-plus-drug coatings," the Frost & Sullivan award announcement notes. "MIVT's Hydroxyapatite (HAp) coatings are entirely biocompatible and promote tissue healing while demonstrating the optimal growth of endothelium. It is in acknowledgement of the company's development of such breakthrough advanced biocompatible medical coatings for stents and other medical devices that it has been recognized with Frost & Sullivan's prestigious Award for Technology Innovation."

Frost & Sullivan's 115-page comprehensive research service entitled, "Advances in Coatings Technology for Medical Devices and Drug Delivery" contains an extensive analysis of MIVT's technology and development initiatives.

Frost & Sullivan's Technical Insights Group discussed the development of MIV Therapeutics' pioneering, completely biocompatible Hydroxyapatite (HAp) technology for medical coatings, and its potential to improve stents and other implantable devices, as well as advanced drug delivery systems. The research service reviews current medical device coatings technologies, innovations, and market trends. The research service on MIVT can be purchased through the Frost & Sullivan website at http://www.frost.com.

MIV Therapeutics is developing and pursuing the commercialization of safe and fully biocompatible coatings for stents and other medical devices with the intent of providing improved solutions for the treatment of cardiovascular disease and other conditions. In collaboration with the University of British Columbia, MIVT is focused on developing a proprietary ultra-thin coating formulation to protect surrounding tissue from chemical interaction with bare-metal stents, an interaction which typically causes aggressive response of the immune system resulting in elevated restenosis, or renarrowing of arteries, and a risk of thrombus in the stented artery. MIVT's innovative coatings are based upon a natural material, Hydroxyapatite, a component of hard tissue found in certain parts of the human body, such as bone, which enables the surface of metallic stents to virtually mimic the natural state of structurally-sound 100% biocompatible and bio-active tissue.

"The Frost & Sullivan Technology Innovation Award is the latest validation of our innovative development of our next-generation Hydroxyapatite coatings for stents and other implantable medical devices," said Alan Lindsay, CEO of MIVT. "It's particularly rewarding that an organization of Frost & Sullivan's caliber and reputation singled out MIVT as a leader in the large and important medical coatings sector. This award provides yet another indication of the potential of our advanced coating solutions to provide significant impact on multimillion-dollar biomedical market sectors. We are certainly proud of this recognition and believe that our technology will continue to set benchmarks for the next-generation bio-friendly coatings in numerous cardiovascular and other medical device segments worldwide."

Unlike stent and drug-eluting coatings currently in use, MIVT's HAp coatings are designed to inhibit adverse reactions of the body immune system. Exceptional biocompatibility and safety of HAp coatings are believed to be the key attributes that may potentially help to reduce restenosis, or re-blocking of the arteries following angioplasty. In particular, MIVT's coatings are designed to reduce risks of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. MIVT has successfully completed a comprehensive range of biocompatibility and histopathology tests on its product and recently completed, with very encouraging results, a 3-month phase of porcine animal trials that confirmed exceptional safety and biocompatibility of HAp coatings in coronary arteries. Human clinical trials are expected to commence soon. MIVT believes its technology also has potential for an array of additional medical applications, including dental, hip and bone repair implants.

[setravis]

 

MIV THERAPEUTICS INC (OTC BB:MIVT.OB) Delayed quote data 

Last Trade: 1.635
Trade Time: 10:55AM ET
Change:  0.145 (9.73%)
Prev Close: 1.49
Open: 1.56
Bid: 1.64 x 500
Ask: 1.64 x 500
1y Target Est: N/A

  Day's Range: 1.55 - 1.75
52wk Range: 0.16 - 1.50
Volume: 1,775,628
Avg Vol (3m): 417,192
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)

[setravis]

Good evening all. I just got in, had a busy day with other things to do.
Was unable to be with you all here at 3SOF. I trust you all made some money without me.

A nice day.
Today a White Candlestick was formed. This represents normal buying pressure.
The last two candlesticks formed a Bullish Harami Pattern . This is a bullish reversal pattern that marks a potential change in trend. However, its reliability is low and it definitely requires confirmation.
Support @ 0.85...0.74...0.68
Resistance @ $1.41
MACD is Bullish
Stochastic is bearish

Technicals
Percentage Gainer

Last Price Quote is:
25.83%above 13-day EMA
69.58%above 50-day EMA

[setravis]

Press Release Source: BiomedDiscoveries.com


MIV Therapeutics Provides Details on Proprietary Hydroxyapatite (HAp) Technology in Online Interview With BiomedDiscoveries.com
Wednesday August 31, 4:01 pm ET
Dr. Tom Troczynski Details Company's Biocompatible Coating Applications and Upcoming Medical Milestones


LOS ANGELES, Aug. 31, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.biomeddiscoveries.com, the online source for exclusive investor information in the biotechnology sector, has announced the online availability of an audio interview with Dr. Tom Troczynski, Professor of Ceramics at The University of British Columbia and Vice President of Coatings at MIV Therapeutics (OTC BB:MIVT.OB - News), a developer of next-generation biocompatible coatings and drug delivery technologies.


Dr. Troczynski's lifetime dedication to the materials and bio-ceramics field has focused on the development of biocompatible hydroxyapatite (HAp) coatings for metallic substrates, such as medical devices, implants and stents. Dr. Troczynski is a Professor of Metals and Materials Engineering at The University of British Columbia in the Department of Metals and Materials Engineering. He has published many articles in journals and other publications, as well as filed a number of patents. Dr. Troczynski is a world-class expert in ceramic technologies; he is a frequent speaker at international symposia and scientific forums, and a recognized authority in his field.

In the audio interview, Dr. Troczynski discusses MIVT's recent recognition by Frost & Sullivan, a widely respected global independent research and growth consulting firm, with the annual Technology Innovation Award, along with detailed information regarding MIVT's proprietary biocompatible coating technologies. ``Hydroxyapatite coatings are the next-generation for the medical industry,'' said Dr. Troczynski. ``Since it is a naturally occurring substance in everyone, many are recognizing that it is the wave of the future for stents and implantable medical devices.''

Dr. Troczynski also discusses MIVT's upcoming research and medical milestones for the coming six months, including important animal studies of the Company's novel biocompatible and drug-eluting coatings for vascular stents and other medical devices. ``We have a very detailed R & D program and we do have some very important milestones. We're going through a series of animal studies; we've finished several series so far. We're moving towards a new series of studies, potentially large trial studies which will be completed sometime in Spring 2006. The next step is to go into human trials.''

The streaming audio interview can be accessed at http://www.biomeddiscoveries.com. Registration to listen to the interview is free.

About MIV Therapeutics, Inc.

MIV Therapeutics Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide attractive alternative solutions to polymer-based drug eluting coatings, currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004, MIVT received a Government grant for the research program titled ``Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents'' under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

About BiomedDiscoveries.com

BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information focused on biotechnology-related companies and developments in the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.biomeddiscoveries.com.

Forward-Looking Statements

Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by BiomedDiscoveries.com

Compensation and Other Disclosures

BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from MIV Therapeutics of $10,000 per month through November 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. Trilogy has non-transferable warrants from this company to purchase 2,720,000 shares of common stock for $0.26 per share and expiring in November 2007, provided that Trilogy may not exercise the warrants to the extent that following such exercise Trilogy would beneficially own 5% or more or the outstanding common stock of this company.



Contact:
          BiomedDiscoveries.com
          Astra Thomas
          (800) 592-6061


--------------------------------------------------------------------------------
Source: BiomedDiscoveries.com

[422fwhp]

MIV Technologies Research Note Issued by Investrend Research Affiliate Beacon Equity Research Regarding New Patent Filing
http://biz.yahoo.com/bw/050902/25117.html?.v=1

MIV Therapeutics' Newest Technology Breakthrough Expands Family of Proprietary ``Smart'' Drug Delivery Systems
http://biz.yahoo.com/bw/050902/25424.html?.v=1

Holding pretty good, imo.

[setravis]

Moving on up....
+7.46%.......Volume......425,945

[setravis]

End of day chart
Holding up very nice....

[setravis]

• MIV THERAPEUTICS INC Files SEC form 8-K, Change in Accountant, Financial Statements and Exhibits
EDGAR Online (Wed 4:05pm) 

))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))

MIV THERAPEUTICS INC (OTC BB:MIVT.OB) Delayed quote data 

Last Trade: 1.50
Trade Time: 1:52PM ET
Change:  0.06 (4.17%)
Prev Close: 1.44
Open: 1.47
Bid: 1.49 x 500
Ask: 1.50 x 500
1y Target Est: N/A

  Day's Range: 1.45 - 1.59
52wk Range: 0.16 - 1.75
Volume: 451,246
Avg Vol (3m): 522,075
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)

[setravis]

Looking good....

[422fwhp]

Correction:  it LOOKED good 

It ended up closing down a bit but imo that was probably just profit taking, wouldn't you say?

I'm still up ~20% and I APPLAUD you for that!  Assessment?

[422fwhp]

...also, would someone educate me on how to read a Point and Figure chart?  ...or a book.

Up looks good to me.   

[422fwhp]

Would someone give a TA assessment?  Thank you.